High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk Hodgkin's lymphoma

Hematology

Volumn 17, Issue 1, 2012, Pages 23-27

  Di Ianni, Mauro ^a   Ballanti, Stelvio ^a   Iodice, Giuseppe ^b   Reale, Antonia ^b   Falzetti, Franca ^a   Minelli, Olivia ^c   Serio, Gabriella ^b   Martelli, Massimo F ^a   Dammacco, Franco ^b   Vacca, Angelo ^b   Ria, Roberto ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^c Perugia General Hospital   (Italy)

Author keywords

Autologous stem cell transplantation; Conditioning regimen; High dose chemotherapy; Hodgkin's lymphoma; Survival

Indexed keywords

ANTIBIOTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; MESNA; METHENAMINE; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA; VINBLASTINE; VINCRISTINE;

ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HODGKIN DISEASE; HUMAN; INFECTION; LEUKOPENIA; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; PYREXIA IDIOPATHICA; SALVAGE THERAPY; STAPHYLOCOCCUS INFECTION; STEM CELL MOBILIZATION; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARBOPLATIN; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; SURVIVAL RATE; THIOTEPA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINBLASTINE; YOUNG ADULT;

EID: 84863085599     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453312X13221316477534     Document Type: Article

References (22)

1. Parkin DM, Muir CS. Cancer incidence in five continents. Comparability and quality of date. Washington, DC: IARC Press, 1992: 45-173.
2. Armitage JO, Bierman PJ, Vose JM, Anderson JR, Weisenburger DD, Kessinger A, et al. Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease. Am J Med. 1991;91:605-611.
3. Carella AM, Congiu AM, Gaozza E, Mazza P, Ricci P, Visani G, et al. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: An Italian study group report. J Clin Oncol. 1988;6:1411-1416.
4. Jagannath S, Dicke KA, Armitage JO, Cabanillas FF, Horwitz LJ, Vellekoop L, et al. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med. 1986;104:163-168.
5. Phillips GL, Wolff SN, Herzig RH, Lazarus HM, Fay JW, Lin HS, et al. Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood. 1989;73:2086-2092.
6. Moskowitz C. An update on the management of relapsed and primary refractory Hodgkin's disease. Semin Oncol. 2004; 31(Suppl):54-59.
7. Kremens B, Wieland R, Reinhard H, Neubert D, Beck JD, Klingebiel T, et al. High-dose chemotherapy with autologous stem cell rescue in children with retinoblastoma. Bone Marrow Transplant. 2003;31:281-284.
8. Fontelonga A, Kelly AJ, MacKintosh FR, Hall S, Monroe P, Wilson GS, et al. A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma. Bone Marrow Transplant. 1997;19:983-988.
9. Chaudhary UB, Damon LE, Rugo HS, Linker CA, Navarro W, Small EJ. High-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell cancer. Am J Clin Oncol. 2005;28:130-137.
10. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6:1562-1568.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;135:185.
12. Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood. 2000;96:1280-1286.
13. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol. 2002;20:221-230.
14. Bonfante V, Santoro A, Viviani S, Devizzi L, Balzarotti M, Soncini F, et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol. 1997;15:528-534.
15. Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood. 1993;81:1137-1145.
16. Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood. 1997;89:801-813.
17. Sweetenham JW, Carella AM, Taghipour G, Cunningham D, Marcus R, Della Volpe A, et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol. 1999;17:3101-3109.
18. Lazarus HM, Rowlings PA, Zhang MJ, Vose JM, Armitage JO, Bierman PJ, et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 1999;17:534-545.
19. Longo DL, Duffey PL, Young RC, Hubbard SM, Ihde DC, Glatstein E, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol. 1992;10:210-218.
20. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bonemarrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet. 1993;341:1051-1054.
21. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet. 2002;359:2065-2071.
22. Brice P, Bastion Y, Divine M, Nedellec G, Ferrant A, Gabarre J, et al. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients. Cancer. 1996;78: 1239-1244.